vs
Side-by-side financial comparison of Medpace Holdings, Inc. (MEDP) and Virtu Financial, Inc. (VIRT). Click either name above to swap in a different company.
Virtu Financial, Inc. is the larger business by last-quarter revenue ($1.1B vs $708.5M, roughly 1.5× Medpace Holdings, Inc.). Virtu Financial, Inc. runs the higher net margin — 31.6% vs 19.1%, a 12.6% gap on every dollar of revenue. On growth, Medpace Holdings, Inc. posted the faster year-over-year revenue change (32.0% vs 30.7%). Over the past eight quarters, Virtu Financial, Inc.'s revenue compounded faster (25.7% CAGR vs 17.7%).
Medpace Holdings, Inc. is a global clinical research organization (CRO) based in Cincinnati, Ohio, employing approximately 6,000 people. Operating under a full-service model, the company also offers global central laboratory, imaging core laboratory, and bioanalytical laboratory services, as well as a Phase I unit located on its headquarters and clinical research campus in Cincinnati, Ohio.
Virtu Financial, Inc. is an American high-frequency trading company. The company went public on the Nasdaq in 2015.
MEDP vs VIRT — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $708.5M | $1.1B |
| Net Profit | $135.1M | $346.6M |
| Gross Margin | — | — |
| Operating Margin | 21.6% | 37.4% |
| Net Margin | 19.1% | 31.6% |
| Revenue YoY | 32.0% | 30.7% |
| Net Profit YoY | 15.5% | 82.8% |
| EPS (diluted) | $4.65 | $1.99 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $1.1B | ||
| Q4 25 | $708.5M | $969.9M | ||
| Q3 25 | $659.9M | $824.8M | ||
| Q2 25 | $603.3M | $999.6M | ||
| Q1 25 | $558.6M | $837.9M | ||
| Q4 24 | $536.6M | $834.3M | ||
| Q3 24 | $533.3M | $706.8M | ||
| Q2 24 | $528.1M | $693.0M |
| Q1 26 | — | $346.6M | ||
| Q4 25 | $135.1M | $139.9M | ||
| Q3 25 | $111.1M | $77.6M | ||
| Q2 25 | $90.3M | $151.2M | ||
| Q1 25 | $114.6M | $99.7M | ||
| Q4 24 | $117.0M | $94.1M | ||
| Q3 24 | $96.4M | $60.0M | ||
| Q2 24 | $88.4M | $66.6M |
| Q1 26 | — | 37.4% | ||
| Q4 25 | 21.6% | 35.4% | ||
| Q3 25 | 21.5% | 21.8% | ||
| Q2 25 | 20.9% | 34.7% | ||
| Q1 25 | 20.3% | 26.7% | ||
| Q4 24 | 23.4% | 24.3% | ||
| Q3 24 | 21.1% | 20.8% | ||
| Q2 24 | 19.9% | 22.4% |
| Q1 26 | — | 31.6% | ||
| Q4 25 | 19.1% | 14.4% | ||
| Q3 25 | 16.8% | 9.4% | ||
| Q2 25 | 15.0% | 15.1% | ||
| Q1 25 | 20.5% | 11.9% | ||
| Q4 24 | 21.8% | 11.3% | ||
| Q3 24 | 18.1% | 8.5% | ||
| Q2 24 | 16.7% | 9.6% |
| Q1 26 | — | $1.99 | ||
| Q4 25 | $4.65 | $1.54 | ||
| Q3 25 | $3.86 | $0.86 | ||
| Q2 25 | $3.10 | $1.65 | ||
| Q1 25 | $3.67 | $1.08 | ||
| Q4 24 | $3.67 | $1.03 | ||
| Q3 24 | $3.01 | $0.64 | ||
| Q2 24 | $2.75 | $0.71 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $497.0M | $973.2M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $459.1M | $2.2B |
| Total Assets | $2.0B | $25.1B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $973.2M | ||
| Q4 25 | $497.0M | $1.1B | ||
| Q3 25 | $285.4M | $707.9M | ||
| Q2 25 | $46.3M | $752.1M | ||
| Q1 25 | $441.4M | $723.6M | ||
| Q4 24 | $669.4M | $872.5M | ||
| Q3 24 | $656.9M | $701.4M | ||
| Q2 24 | $510.9M | $684.8M |
| Q1 26 | — | — | ||
| Q4 25 | — | $2.0B | ||
| Q3 25 | — | $2.0B | ||
| Q2 25 | — | $1.7B | ||
| Q1 25 | — | $1.7B | ||
| Q4 24 | — | $1.7B | ||
| Q3 24 | — | $1.7B | ||
| Q2 24 | — | $1.7B |
| Q1 26 | — | $2.2B | ||
| Q4 25 | $459.1M | $1.6B | ||
| Q3 25 | $293.6M | $1.5B | ||
| Q2 25 | $172.4M | $1.4B | ||
| Q1 25 | $593.6M | $1.3B | ||
| Q4 24 | $825.5M | $1.3B | ||
| Q3 24 | $881.4M | $1.2B | ||
| Q2 24 | $763.6M | $1.2B |
| Q1 26 | — | $25.1B | ||
| Q4 25 | $2.0B | $20.2B | ||
| Q3 25 | $1.8B | $21.3B | ||
| Q2 25 | $1.6B | $19.3B | ||
| Q1 25 | $1.9B | $17.5B | ||
| Q4 24 | $2.1B | $15.4B | ||
| Q3 24 | $2.1B | $14.4B | ||
| Q2 24 | $1.9B | $13.9B |
| Q1 26 | — | — | ||
| Q4 25 | — | 1.29× | ||
| Q3 25 | — | 1.40× | ||
| Q2 25 | — | 1.24× | ||
| Q1 25 | — | 1.33× | ||
| Q4 24 | — | 1.39× | ||
| Q3 24 | — | 1.41× | ||
| Q2 24 | — | 1.41× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $192.7M | — |
| Free Cash FlowOCF − Capex | $188.1M | — |
| FCF MarginFCF / Revenue | 26.6% | — |
| Capex IntensityCapex / Revenue | 0.6% | — |
| Cash ConversionOCF / Net Profit | 1.43× | — |
| TTM Free Cash FlowTrailing 4 quarters | $681.9M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $192.7M | $518.4M | ||
| Q3 25 | $246.2M | $-68.7M | ||
| Q2 25 | $148.5M | $62.8M | ||
| Q1 25 | $125.8M | $15.0M | ||
| Q4 24 | $190.7M | $599.0M | ||
| Q3 24 | $149.1M | $112.1M | ||
| Q2 24 | $116.4M | $490.8M |
| Q1 26 | — | — | ||
| Q4 25 | $188.1M | $495.6M | ||
| Q3 25 | $235.5M | $-76.7M | ||
| Q2 25 | $142.4M | $57.6M | ||
| Q1 25 | $115.8M | $9.2M | ||
| Q4 24 | $183.0M | $586.6M | ||
| Q3 24 | $138.5M | $106.2M | ||
| Q2 24 | $103.5M | $486.9M |
| Q1 26 | — | — | ||
| Q4 25 | 26.6% | 51.1% | ||
| Q3 25 | 35.7% | -9.3% | ||
| Q2 25 | 23.6% | 5.8% | ||
| Q1 25 | 20.7% | 1.1% | ||
| Q4 24 | 34.1% | 70.3% | ||
| Q3 24 | 26.0% | 15.0% | ||
| Q2 24 | 19.6% | 70.3% |
| Q1 26 | — | — | ||
| Q4 25 | 0.6% | 2.4% | ||
| Q3 25 | 1.6% | 1.0% | ||
| Q2 25 | 1.0% | 0.5% | ||
| Q1 25 | 1.8% | 0.7% | ||
| Q4 24 | 1.4% | 1.5% | ||
| Q3 24 | 2.0% | 0.8% | ||
| Q2 24 | 2.4% | 0.6% |
| Q1 26 | — | — | ||
| Q4 25 | 1.43× | 3.71× | ||
| Q3 25 | 2.22× | -0.89× | ||
| Q2 25 | 1.65× | 0.42× | ||
| Q1 25 | 1.10× | 0.15× | ||
| Q4 24 | 1.63× | 6.37× | ||
| Q3 24 | 1.55× | 1.87× | ||
| Q2 24 | 1.32× | 7.37× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MEDP
| Metabolic | $249.8M | 35% |
| Oncology | $195.9M | 28% |
| Other | $88.3M | 12% |
| Central Nervous System | $73.2M | 10% |
| Cardiology | $63.0M | 9% |
| Antiviral And Anti Infective | $38.3M | 5% |
| Related Party | $10.3M | 1% |
VIRT
| Trading income, net | $789.1M | 72% |
| Commissions, net and technology services | $186.6M | 17% |
| Other | $119.6M | 11% |
